ISSN 0033-2917; 1469-8978;
7 papers in the library · 26 citations · publishing 2008-2025
Psychol Med August 26, 2025 Michael Angyus, Sarah Osborn, Eline Haijen et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Psychol Med March 31, 2025 Otto Simonsson, Simon B. Goldberg, Walter Osika et al. 16 citations
BACKGROUND: Findings from contemporary clinical trials suggest that psychedelics are generally safe and may be effective in the treatment of various psychiatric disorders. However, less is known about the risks associated with psychedelic use outside of medically supervised contexts, particularly in populations that are typically excluded from participation in clinical trials. METHODS:...
Psychol Med September 27, 2024 Michael Angyus, Sarah Osborn, Eline Haijen et al. 10 citations
Abstract Background Access to psychedelic drugs is liberalizing, yet responses are highly unpredictable. It is therefore imperative that we improve our ability to predict the nature of the acute psychedelic experience to improve safety and optimize potential therapeutic outcomes. This study sought to validate the ‘Imperial Psychedelic Predictor Scale’ (IPPS), a short, widely applicable,...
Psychol Med August 1, 2011
Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines?
Psychol Med July 7, 2011
Subjective experience and meaning of psychoses: the German Subjective Sense in Psychosis Questionnaire (SUSE).
Psychol Med December 23, 2010
Response to 'A systematic review of neurobiological and clinical features of mindfulness meditations'.
Psychol Med November 12, 2008
The role of metacognitive beliefs in determining the impact of anomalous experiences: a comparison of help-seeking and non-help-seeking groups of people experiencing psychotic-like anomalies.